atrial-natriuretic-factor and Ileus

We studied the effectiveness of human atrial natriuretic peptide (hANP) on management of acute kidney injury.. This retrospective single-center study included 43 patients from January 2007 to February 2010 who had undergone non-elective abdominal surgery for gastrointestinal perforation and ileus. Patients were separated into 2 groups according to whether hANP was administered or not, and 4 subgroups according to whether or not baseline serum creatinine <1.2 mg/dL; normal cre/hANP (-) (n = 22), high cre/hANP (-) (n = 10), normal cre/hANP (+) (n = 4), and high cre/hANP (+) (n = 7). The administration of hANP was started during operation.. The administration rate of hANP ranged between 0.02 and 0.05 μg/kg per minute, except for one patient and the average postoperative administration time of hANP was 167 ± 237 h (range, 8-888 h). There were no significant differences in characteristics of patients within four subgroups, except for patient's weight. Serum creatinine in high cre/hANP (+) got to decrease more than high cre/hANP (-). Outcomes such as 28-day mortality were not significantly different among four subgroups. No patients required renal replacement therapy in each subgroup.. Intravenous low dose of hANP was useful as acute kidney injury management in gastrointestinal perforation and ileus patients undergoing non-elective surgery.

Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Comorbidity; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Ileus; Intestinal Perforation; Kidney Function Tests; Male; Perioperative Care; Recombinant Proteins; Retrospective Studies

Topics: Acute Kidney Injury; Atrial Natriuretic Factor; Female; Humans; Ileus; Intestinal Perforation; Male; Perioperative Care